scholarly journals Correlations between Hippocampal Neurogenesis and Metabolic Indices in Adult Nonhuman Primates

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Tarique D. Perera ◽  
Dunyue Lu ◽  
Lakshmi Thirumangalakudi ◽  
Eric L. P. Smith ◽  
Arkadiy Yaretskiy ◽  
...  

Increased neurogenesis in feeding centers of the murine hypothalamus is associated with weight loss in diet-induced obese rodents (Kokoeva et al., 2005 and Matrisciano et al., 2010), but this relationship has not been examined in other species. Postmortem hippocampal neurogenesis rates and premortem metabolic parameters were statistically analyzed in 8 chow-fed colony-reared adult bonnet macaques. Dentate gyrus neurogenesis, reflected by the immature neuronal marker, doublecortin (DCX), and expression of the antiapoptotic gene factor, B-cell lymphoma 2 (BCL-2), but not the precursor proliferation mitotic marker, Ki67, was inversely correlated with body weight and crown-rump length. DCX and BCL-2 each correlated positively with blood glucose level and lipid ratio (total cholesterol/high-density lipoprotein). This study demonstrates that markers of dentate gyrus neuroplasticity correlate with metabolic parameters in primates.

2001 ◽  
Vol 21 (3) ◽  
pp. 211-217 ◽  
Author(s):  
Ekaterina Perfilieva ◽  
Anette Risedal ◽  
Jenny Nyberg ◽  
Barbro B. Johansson ◽  
Peter S. Eriksson

To investigate whether rat hippocampal neurogenesis varies with strain and gender, the authors examined proliferating progenitor cells and their progeny in young male and female Sprague-Dawley (SD) and spontaneously hypertensive rats (SHR) using the thymidine analog bromodeoxyuridine (BrdU) combined with immunohistochemistry for the neuronal marker Calbindin D28k and glial fibrillary acidic protein. Rats were given 7 consecutive daily BrdU injections and were killed 1 day or 4 weeks later to allow for discrimination between proliferation and cell survival. Stereologic analysis of the numbers of BrdU-immunoreactive cells in the dentate gyrus revealed both a strain difference with significantly higher cell proliferation and net neurogenesis in SHR than in SD and a gender difference with males from both strains producing significantly more cells than their female counterparts. Whereas the number of progenitors four weeks after BrdU injections was still significantly greater in male than in female SHRs, resulting in a greater net neurogenesis in the male, the number of BrdU-immunoreactive cells did not differ between male and female SD rats, suggesting a greater survival of newly generated cells in the dentate gyrus in female than in male SD rats. No sex or strain difference was observed in the relative ratio of neurogenesis and gliogenesis.


Author(s):  
Vasilios Pergialiotis ◽  
Eftihios Trakakis ◽  
Christos Parthenis ◽  
Erifili Hatziagelaki ◽  
Charalampos Chrelias ◽  
...  

Abstract Background The purpose of our study is to evaluate the association of platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) with hormonal and metabolic parameters in patients with polycystic ovarian syndrome (PCOS) in order to assess whether these ratios may become useful tools during the evaluation of the severity of low grade inflammation. Methods The present study is based in secondary outcomes from a prospectively collected patient database. A total of 266 women with PCOS participated in this study and blood a complete blood count examination (CBC) that was used for the calculation of PLR and NLR was available in 182 patients. Results Association statistics revealed that PLR had a significant correlation to 17-OH progesterone (r = −0.177, p = 0.024) and Matsuda index values (r = 0.234, p = 0.009), whereas NLR was correlated with follicle stimulating hormone (FSH) (r = −0.204, p = 0.007), free testosterone (r = 320, p < 0.001), Δ4-androstendione (r = 0.234, p = 0.003), sex hormone binding globulin (SHBG) (r = −0.350, p < 0.002) and high-density lipoprotein (HDL) (r = −0.171, p = 0.039). Conclusion According to the findings of our study, both PLR and NLR seem to be correlated with some hormonal and metabolic indices. This association is clearer in the case of NLR and serum androgens as it seems to be positively affected by their levels. PLR and NLR were not affected by the presence of obesity.


Blood ◽  
2016 ◽  
Vol 127 (12) ◽  
pp. 1564-1574 ◽  
Author(s):  
Tibor Bedekovics ◽  
Sajjad Hussain ◽  
Andrew L. Feldman ◽  
Paul J. Galardy

Key Points The neuronal marker UCH-L1 is induced in, and specifically augments the oncogene-induced transformation of, GCB cells. High levels of UCHL1 identify patients with GC DLBCL with an increased risk for poor outcomes.


PLoS ONE ◽  
2011 ◽  
Vol 6 (4) ◽  
pp. e17600 ◽  
Author(s):  
Tarique D. Perera ◽  
Andrew J. Dwork ◽  
Kathryn A. Keegan ◽  
Lakshmi Thirumangalakudi ◽  
Cecilia M. Lipira ◽  
...  

2018 ◽  
Vol 132 (10) ◽  
pp. 1075-1083 ◽  
Author(s):  
Mikaël Croyal ◽  
Thi-Thu-Trang Tran ◽  
Rose Hélène Blanchard ◽  
Jean-Christophe Le Bail ◽  
Elise F. Villard ◽  
...  

Therapeutic antibodies targeting proprotein convertase subtilisin kexin type 9 (PCSK9) (e.g. alirocumab) lower low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in clinical trials. We recently showed that PCSK9 enhances apolipoprotein(a) [apo(a)] secretion from primary human hepatocytes but does not affect Lp(a) cellular uptake. Here, we aimed to determine how PCSK9 neutralization modulates Lp(a) levels in vivo. Six nonhuman primates (NHP) were treated with alirocumab or a control antibody (IgG1) in a crossover protocol. After the lowering of lipids reached steady state, NHP received an intravenous injection of [2H3]-leucine, and blood samples were collected sequentially over 48 h. Enrichment of apolipoproteins in [2H3]-leucine was assessed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Kinetic parameters were calculated using numerical models with the SAAMII software. Compared with IgG1, alirocumab significantly reduced total cholesterol (TC) (−28%), LDL-C (−67%), Lp(a) (−56%), apolipoprotein B100 (apoB100) (−53%), and apo(a) (−53%). Alirocumab significantly increased the fractional catabolic rate of apoB100 (+29%) but not that of apo(a). Conversely, alirocumab sharply and significantly reduced the production rate (PR) of apo(a) (−42%), but not significantly that of apoB100, compared with IgG1, respectively. In line with the observations made in human hepatocytes, the present kinetic study establishes that PCSK9 neutralization with alirocumab efficiently reduces circulating apoB100 and apo(a) levels by distinct mechanisms: apoB primarily by enhancing its catabolism and apo(a) primarily by lowering its production.


2009 ◽  
Vol 54 (No. 4) ◽  
pp. 182-189 ◽  
Author(s):  
M. Okulicz ◽  
I. Hertig ◽  
J. Chichłowska

: Indole-3-carbinol (I3C) was found to have possible anticarcinogenic, antioxidant and anti-atherogenic effects on the organism. So far, its influence on metabolic pathways has been unknown. This work was the first attempt to determine the carbohydrate and lipid metabolism changes <I>in vivo</I> after administration of 150 mg/kg b.wt./day I3C to male rats. Additionally, the aim of this trial was to evaluate the direct effect of I3C on basal and hormone-induced lipogenesis and lipolysis in isolated rat adipocytes at concentrations 1, 10, 100 &mu;M <I>in vitro</I>. We can corroborate that adipocytes are susceptible to the direct action of I3C. The incubation of adipocytes with I3C at the three above-mentioned concentrations resulted in its influence on restriction of glucose entry into adipocytes in the basal as well as insulin-stimulated conditions. However, it was observed that I3C at these concentrations strongly intensified basic and epinephrine-stimulated lipolysis. I3C also has a significant influence on metabolism <I>in vivo</I>. Its administration to rats caused a significant increase in the content of triglycerides and a decrease in glycogen in the liver. The considerable augmentation of glucose, triglycerides, cholesterol in high-density lipoprotein and insulin with a concomitant decrease in FFA concentrations was noted in the blood serum. I3C did not alter phospholipids, total, free, esterified cholesterol in the serum and the liver cholesterol. The results obtained <I>in vivo</I> and <I>in vivo</I> indicate that the effect of I3C is adverse for the majority of metabolic parameters which were investigated. The most important finding in this study is the effect of I3C on liver steatosis and that the observed lower lipogenesis at higher lipolysis in fat cells may be involved in the mechanism.


Blood ◽  
1991 ◽  
Vol 77 (4) ◽  
pp. 750-755 ◽  
Author(s):  
JB Stoudemire ◽  
MB Garnick

Abstract Recombinant human macrophage colony-stimulating factor (rhM-CSF) is a hematopoietic growth factor that stimulates the growth, differentiation, proliferation, and activation of cells of the monocyte/macrophage lineage. rhM-CSF was administered to rabbits and nonhuman primates to evaluate effects on cholesterol homeostasis. Decreases in plasma cholesterol concentrations were observed during rhM- CSF administration. The observed mean (+/- SD) decreases over a range of doses in nonhuman primates receiving rhM-CSF by continuous intravenous infusion (CIVI) or intravenous bolus (IVB) injection were approximately 16% +/- 8% and 43% +/- 10%, respectively. Low-density lipoprotein (LDL) cholesterol levels decreased 55% +/- 9% from pretreatment baseline values in the animals receiving rhM-CSF by IVB. Normocholesterolemic New Zealand white rabbits receiving rhM-CSF over a range of doses by CIVI showed a decrease from baseline in total cholesterol of approximately 28% +/- 17%, with LDL cholesterol levels decreasing by approximately 72% +/- 33%, while high-density lipoprotein levels showed variable changes, including increased values. A decrease of 36% +/- 26% in total plasma cholesterol was observed in Watanabe Heritable Hyperlipidemic rabbits receiving rhM-CSF by CIVI for 7 days. This decrease was attributable almost entirely to decreases in LDL cholesterol, which fell approximately 34% +/- 24% from baseline. Although the mechanism of this cholesterol-lowering effect is unknown, these results strongly suggest that rhM-CSF may provide a novel treatment for hypercholesterolemia and may be useful in investigations into the mechanisms of cholesterol homeostasis and atherogenesis.


Sign in / Sign up

Export Citation Format

Share Document